Stocks Health care EXEL
NASDAQ · Health careExelixis, Inc. (EXEL)
Exelixis, Inc. brought in $2.5B of revenue over the twelve months to October 2, 2026, up 9.1% from a year earlier. Net income was $885.1M, a net margin of 35.5%. Operating cash flow minus capital spending left $875.8M of free cash flow in fiscal 2025. At October 2, 2026 it held $304.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Exelixis, Inc.
- Net worth
- Exelixis, Inc. has a market value (market cap) of $17.5B at the latest share price, and shareholders' equity of $1.8B on its balance sheet at October 2, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.3B (+7.0% year on year), with net income of $782.6M. Over the 12 months to October 2, 2026: revenue $2.5B, net income $885.1M.
- Cash flow
- In fiscal 2025 operations brought in $884.3M of cash; after $8.4M of capital spending, free cash flow was $875.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to October 2, 2026. Open on SEC EDGAR
- Next earnings report
- Exelixis, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Exelixis, Inc. does
Exelixis, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker EXEL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.3B | $782.6M | $2.78 | $875.8M |
| 2024 | $2.2B | $521.3M | $1.76 | $671.5M |
| 2023 | $1.8B | $207.8M | $0.65 | $292.9M |
| 2022 | $1.6B | $182.3M | $0.56 | $334.9M |
| 2021 | $1.4B | $231.1M | $0.72 | $346.6M |
| 2020 | $987.5M | $111.8M | $0.35 | $178.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where EXEL ranks in Health care
Latest SEC filings
What Exelixis, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake (5% or more) SCHEDULE 13G
- November 9, 2026Activist stake changed SCHEDULE 13D/A
- October 29, 2026Quarterly report 10-Q · period to October 2, 2026Revenue rose 10% to $658.7M versus the same quarter last year; diluted EPS $0.85 versus $0.69.
- October 29, 2026
- September 11, 2026Other event 8-K
- August 31, 2026Other event 8-K
- August 14, 2026Activist stake changed SCHEDULE 13D/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026
- August 5, 2026Quarterly report 10-Q · period to July 3, 2026Revenue rose 11% to $628.7M versus the same quarter last year; diluted EPS $0.82 versus $0.65.
What is EXEL worth? A DCF from its reported cash flow
Insider trades
What the people running Exelixis, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 10, 2026 | Beckerle Mary CDirector | Soldpre-planned (10b5-1) | 9,812 | $526.5K |
| June 1, 2026 | Eckhardt Sue GailDirector | Soldpre-planned (10b5-1) | 9,812 | $492K |
| June 1, 2026 | Wyszomierski Jack LDirector | Soldpre-planned (10b5-1) | 3,925 | $198.4K |
| May 27, 2026 | Poste GeorgeDirector | Received as pay | 8,367 | - |
| May 27, 2026 | Wyszomierski Jack LDirector | Received as pay | 8,367 | - |
| May 27, 2026 | Oliver BobDirector | Received as pay | 8,367 | - |
| May 27, 2026 | Beckerle Mary CDirector | Received as pay | 8,367 | - |
| May 27, 2026 | Freire Maria CDirector | Received as pay | 8,367 | - |
Who owns EXEL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Joshua J. Dapice13D, may seek influence with 29 related filers | 9.2% | May 8, 2024 |
| Farallon Capital Management, L.L.C.13G, passive with 15 related filers | 6% | November 9, 2026 |
| Dapice Joshua J.13D, may seek influence with 30 related filers | 5.9% | January 5, 2026 |
| Vanguard Capital Management13G, passive | 5.09% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 756 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 29,075,377 | -1,740,932 |
| Farallon Capital Management, L.L.C. | 13,468,010 | +357,000 |
| Renaissance Technologies LLC | 13,427,993 | -299,000 |
| Vanguard Portfolio Management LLC | 12,043,122 | -42,151 |
| Aqr Capital Management LLC | 11,023,943 | -2,071,798 |
| Vanguard Capital Management LLC | 10,950,997 | -307,987 |
| State Street Corp | 9,970,071 | -328,368 |
| Fuller & Thaler Asset Management, Inc. | 8,929,389 | +387,153 |
| Geode Capital Management, LLC | 7,650,316 | -145,294 |
| D. E. Shaw & Co., Inc. | 5,551,747 | +1,948,684 |
| Morgan Stanley | 4,519,684 | +341,448 |
| Invesco Ltd. | 4,495,697 | +181,316 |
| Dimensional Fund Advisors LP | 4,426,620 | +127,023 |
| Arrowstreet Capital, Limited Partnership | 4,365,926 | -468,699 |
| Two Sigma Investments, LP | 4,209,861 | +2,003,649 |
| Assetmark, Inc | 3,433,824 | +44,904 |
| Nuveen, LLC | 3,276,984 | -505,750 |
| UBS Group AG | 3,167,890 | +774,377 |
| Stephens Investment Management Group LLC | 2,710,011 | +185,511 |
| Goldman Sachs Group Inc | 2,690,489 | +571,915 |
Insiders
15 insiders reported holding 8,790,670 shares in total, about $620.4M at the last price.
| Holder | Shares |
|---|---|
| Morrissey MichaelPresident and CEO, Director | 3,366,3352,004,327 held indirectly |
| Johnson David EdwardDirector | 1,553,2621,553,262 held indirectly |
| Papadopoulos SteliosDirector | 1,197,595 |
| Senner Christopher J.EVP and CFO | 952,317 |
| Aftab DanaEVP, Research and Development | 594,741 |
| Haley Patrick J.EVP, Commercial | 357,638 |
| Wyszomierski Jack LDirector | 284,384 |
| Poste GeorgeDirector | 127,199 |
| Freire Maria CDirector | 109,186 |
| Hefti BrendaSVP and General Counsel | 106,762 |
Questions about EXEL
What does Exelixis, Inc. do?
Exelixis, Inc. is a company in the Health care sector, listed on NASDAQ as EXEL. Its shares trade on NASDAQ under the ticker EXEL.
What is Exelixis, Inc.'s net worth?
Exelixis, Inc. has a market value (market cap) of $17.5B at the latest share price, and shareholders' equity of $1.8B on its balance sheet at October 2, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Exelixis, Inc. profitable?
Yes. Over the twelve months to October 2, 2026 it reported net income of $885.1M on revenue of $2.5B, a net margin of 35.5%.
How much revenue does Exelixis, Inc. make?
Over the twelve months to October 2, 2026 Exelixis, Inc. reported revenue of $2.5B. That is 9.1% more than a year earlier.
When did Exelixis, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to October 2, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 9, 2026.
When is Exelixis, Inc.'s next earnings report?
Exelixis, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare EXEL with
Follow EXEL
Get an email when Exelixis, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Exelixis, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.